Implantica publishes Annual Report 2022
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2022. The annual report is now available on the company’s website.
“During 2022 RefluxStop™ continued to disrupt the field of anti-reflux treatments with its unique breakthrough approach and excellent patient outcomes. Our main focus remains building and scaling our top commercial priority RefluxStop™ through reimbursement (market access) to become an exceptional growth story,” says Peter Forsell, CEO of Implantica.
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, email@example.com
The information was sent for publication, through the agency of the contact person set out above, on April 20, 2023, at 08:30 a.m. CET.
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
VP Marketing & Advocacy
M: +1 925-381-4581